rss
Heart 91:324-328 doi:10.1136/hrt.2004.037481
  • Cardiovascular medicine

Giant cell arteritis and cardiovascular disease in older adults

  1. J G Ray1,
  2. M M Mamdani2,*,
  3. W H Geerts3
  1. 1Department of Medicine, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada
  2. 2Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
  3. 3Department of Medicine, Sunnybrook and Women’s College Health Sciences Centre, Toronto, Ontario, Canada
  1. Correspondence to:
    Dr Joel G Ray
    Department of Medicine, Inner City Health, St Michael’s Hospital, 30 Bond Street, Toronto, Ontario, Canada M5B 1W8; JRay515445aol.com
  • Accepted 10 May 2004

Abstract

Objective: To explore the association between giant cell arteritis (GCA) and subsequent cardiovascular disease in older adults.

Design: Population based retrospective cohort study.

Setting: The entire province of Ontario, Canada.

Participants: Patients aged 66 years and older with newly diagnosed GCA (n = 1141), osteoarthritis (n = 172 953), or neither (n = 200 000). Patients with neither were randomly selected from the general population and formed the control group.

Main outcome measures: The primary composite outcome was based on a subsequent diagnosis or surgical treatment for coronary artery disease, stroke, peripheral arterial disease, or aneurysm or dissection of the aorta.

Results: The composite end point was more common in seniors with GCA (12.1/1000 person-years) than in patients with osteoarthritis (7.3/1000 person-years) or neither condition (5.3/1000 person-years). The adjusted hazard ratio for cardiovascular disease was 1.6 (95% confidence interval (CI) 1.1 to 2.2) in patients with GCA versus patients with osteoarthritis, and 2.1 (95% CI 1.5 to 3.0) in patients with GCA versus unaffected controls.

Conclusions: Older adults with GCA appear to be at increased risk for developing cardiovascular disease. Whether an aggressive approach to cardiovascular risk factor modification is particularly beneficial in these patients remains to be determined.

Footnotes

  • * Also the Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada

  • Potential conflict of interest: none.